Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2006 1
2007 2
2008 1
2009 3
2010 4
2011 1
2012 10
2013 12
2014 9
2015 9
2016 14
2017 9
2018 7
2019 14
2020 13
2021 12
2022 14
2023 10
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of life.
Keetharuth AD, Gould RL, McDermott CJ, Thompson BJ, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton EJ, Tappenden P, White D, Howard RJ, Serfaty MA, McCracken LM, Graham CD, Al-Chalabi A, Goldstein LH, Lawrence V, Cooper C, Young T; COMMEND Collaboration Group. Keetharuth AD, et al. Among authors: mcdermott cj. Eur J Neurol. 2024 Apr 25:e16317. doi: 10.1111/ene.16317. Online ahead of print. Eur J Neurol. 2024. PMID: 38660985
Non-negative matrix factorisation of Raman spectra finds common patterns relating to neuromuscular disease across differing equipment configurations, preclinical models and human tissue.
Alix JJP, Plesia M, Schooling CN, Dudgeon AP, Kendall CA, Kadirkamanathan V, McDermott CJ, Gorman GS, Taylor RW, Mead RJ, Shaw PJ, Day JC. Alix JJP, et al. Among authors: mcdermott cj. J Raman Spectrosc. 2023 Mar;54(3):258-268. doi: 10.1002/jrs.6480. Epub 2022 Dec 22. J Raman Spectrosc. 2023. PMID: 38505661 Free PMC article.
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).
Van Damme P, Al-Chalabi A, Andersen PM, Chiò A, Couratier P, De Carvalho M, Hardiman O, Kuźma-Kozakiewicz M, Ludolph A, McDermott CJ, Mora JS, Petri S, Probyn K, Reviers E, Salachas F, Silani V, Tysnes OB, van den Berg LH, Villanueva G, Weber M. Van Damme P, et al. Among authors: mcdermott cj. Eur J Neurol. 2024 Mar 12:e16264. doi: 10.1111/ene.16264. Online ahead of print. Eur J Neurol. 2024. PMID: 38470068
Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Harrower T, Orrell RW, Annadale J, Hanemann CO, Scalfari A, Tennant A, Mills R; TONIC-ALS STUDY GROUP. Young CA, et al. Among authors: mcdermott cj. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Mar 11:1-11. doi: 10.1080/21678421.2024.2322545. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38465877
Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Young CA, Chaouch A, Mcdermott CJ, Al-Chalabi A, Chhetri SK, Talbot K, Malaspina A, Mills R, Tennant A. Young CA, et al. Among authors: mcdermott cj. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):400-409. doi: 10.1080/21678421.2024.2322539. Epub 2024 Mar 1. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38426231 Free article.
Supporting people with Motor Neuron Disease (MND) to make decisions about gastrostomy feeding tube placement: a survey of UK healthcare professionals' practice and beliefs.
White S, O'Cathain A, Halliday V, Bradburn M, McDermott CJ. White S, et al. Among authors: mcdermott cj. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):290-298. doi: 10.1080/21678421.2024.2314061. Epub 2024 Feb 9. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38337170 Free article.
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Nicolini G, Vanacore N, Dickie B, Albanese A, Puopolo M; TUDCA-ALS Study Group. Lombardo FL, et al. Among authors: mcdermott cj. Trials. 2023 Dec 5;24(1):792. doi: 10.1186/s13063-023-07638-w. Trials. 2023. PMID: 38053196 Free PMC article. Clinical Trial.
129 results